These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15277624)

  • 1. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.
    Baseman DG; O'Suilleabhain PE; Reimold SC; Laskar SR; Baseman JG; Dewey RB
    Neurology; 2004 Jul; 63(2):301-4. PubMed ID: 15277624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
    Van Camp G; Flamez A; Cosyns B; Goldstein J; Perdaens C; Schoors D
    Neurology; 2003 Sep; 61(6):859-61. PubMed ID: 14504342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB; Reimold SC; O'Suilleabhain PE
    Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valvular heart disease in patients taking pergolide.
    Pritchett AM; Morrison JF; Edwards WD; Schaff HV; Connolly HM; Espinosa RE
    Mayo Clin Proc; 2002 Dec; 77(12):1280-6. PubMed ID: 12479512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
    Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
    J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valvular heart disease in patients taking pergolide.
    Waller EA; Kaplan J; Heckman MG
    Mayo Clin Proc; 2005 Aug; 80(8):1016-20. PubMed ID: 16092580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valvular heart disease in pergolide-treated Parkinson's disease.
    Scozzafava J; Takahashi J; Johnston W; Puttagunta L; Martin WR
    Can J Neurol Sci; 2006 Feb; 33(1):111-3. PubMed ID: 16583734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
    Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
    J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
    N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regurgitant valvular disease prevalence and progression found on echocardiogram in military aviators.
    Davis SM; Davenport ED; Haynes JT; Alvarado RL
    Aviat Space Environ Med; 2014 Oct; 85(10):1013-8. PubMed ID: 25245901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reversible cardiac valve abnormalities with pergolide treatment].
    Calomne V; Dupuis MJ; Muller T; Kempinere F
    Rev Neurol (Paris); 2004 Jan; 160(1):81-2. PubMed ID: 14978397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doppler echocardiographic evaluation of valve regurgitation in healthy volunteers.
    Jobic Y; Slama M; Tribouilloy C; Lan Cheong Wah L; Choquet D; Boschat J; Penther P; Lesbre JP
    Br Heart J; 1993 Feb; 69(2):109-13. PubMed ID: 8435234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 20. Valvular heart disease associated with fenfluramine-phentermine.
    Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
    N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.